Navigation Links
NanoMaterials Technology to Conduct Process Development Feasibility Study with US Based Emerging Pharmaceutical Company
Date:10/25/2007

SINGAPORE, Oct. 25 /Xinhua-PRNewswire/ -- NanoMaterials Technology ("NMT") announced that it will conduct a feasibility study with a US based emerging pharmaceutical company.

As part of the feasibility agreement, NMT will apply its proprietary technology, High Gravity Controlled Precipitation (HGCP), to the design of drug particles for pulmonary inhalation.

"Altering the particle design of drug compounds changes the physical properties of the drugs and this leads to enhanced drug efficacy and patient compliance," says Dr Jimmy Yun, the CEO of NMT. NMT's niche in the pharmaceutical industry is in particle design and the company is currently focusing its development on solid oral and inhalation delivery.

NMT is also currently in talks with pharmaceutical companies in the US and Europe for several development agreements. As part of its drive into the pharmaceutical sector, NMT has appointed John Mitchell and Prof. Dr. Siegfried Neumann to its Scientific Advisory Board ("SAB").

John Mitchell retired from Pfizer Inc as Senior Vice President and President/Team Leader, Pfizer Global Manufacturing at the end of 2004. While at Pfizer, he was responsible for worldwide manufacturing operations that produced pharmaceutical, consumer healthcare and animal health products, encompassing plants and logistics centers at more than 120 sites in 40 countries.

John holds a Bachelor of Engineering degree from Yale University and an honorary Doctor of Laws degree from the National University of Ireland.

Prof. Neumann is currently a Senior Consultant of R&D at Merck KGaA. At Merck KGaA, Prof. Neumann was a group leader in R&D in the Diagnostic Division until 1985. He subsequently headed up the Immunochemistry Department in Preclinical Research at Merck Pharma until 1989 when he returned as the Head of R&D of the Diagnostic Division. In 1994, he moved on to head up the Business Development and Research Alliance Office in Specialty Chemistry and Biotechnology. Prof. Neumann has an established track record in technology scouting and evaluation, and participates in various national and international expert panels in the field of biotechnology.

Prof. Neumann received his PhD in biochemistry from the University of Bochum, Germany in 1971.

"It is a great pleasure and honour for us to have both John and Prof. Neumann joining our SAB. Their addition to our SAB is invaluable as they bring with them broad and in-depth experience in the pharmaceutical industry," says Dr. Yun.

About NanoMaterials Technology Pte Ltd ( http://www.nanomt.com )

Founded in April 2000, NanoMaterials Technology (NMT) is a Singapore company that specialises in the development and commercialisation of the production technologies of nanomaterials.

NMT has a proprietary technology called the High Gravity Controlled Precipitation (HGCP). The result of this breakthrough is a nanomaterial production technology that is simple, easy to scale up and extremely cost effective.

Contact Details:

NanoMaterials Technology Pte Ltd

Ms Grace Yeo

Tel: +65-9384-1818

Email: grace.yeo@nanomt.com

Cogent Communications Pte Ltd

Ms Celine Ooi

Tel: +65-6323-1060

Email: celine@cogentcomms.com


'/>"/>
SOURCE NanoMaterials Technology Pte Ltd
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Innovative Tissue Array Technology for High-Throughput Screening of Gene Expression
2. HotMasterAn innovative Hot Start/Cold Stop technology for better PCR* results
3. Enhancing Ruggedness and Full-Scan MS Sensitivity Using Ion Sweep Technology
4. Novel MicroRNA Array Technology for Sensitive miRNA Profiling
5. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
6. Use of FlashPlate Technology for In Vitro Measurement of [35S]-GTPγS Binding in CHO Cells Expressing the Human 5-HT1B Receptor
7. Use of Novel FlashPlate Technology to Measure cAMP Accumulation in Chinese Hamster Ovary Cells Expressing Human -2 Adrenoreceptors
8. Use of FlashPlate Technology for In Vitro Measurement of 125I-Labeled TGF-1 Binding on Chimeric Extracellular Domain of Type II Transforming Growth Factor Receptor
9. DNA purification from pig ears to bird blood using proven DNeasy Technology
10. Near Infrared Technology and Optical Agents For Molecular Imaging
11. Technology helps but the best way to reduce Sarbox cost is with people
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... DIEGO , Feb. 16, 2017  Dermata ... innovative products to treat a variety of dermatological ... million Series 1a financing and entered into a ... (SVB).  Dermata intends to use the capital for ... making major advancements in the treatment of serious ...
(Date:2/16/2017)... BOSTON , Feb. 16, 2017 /PRNewswire/ ... for rare genetic deficiencies that result in ... of a $41 million mezzanine round of ... Ipsen, OrbiMed, MPM Capital, New Enterprise Associates, ... an undisclosed public healthcare investment fund. Rhythm ...
(Date:2/15/2017)... CA (PRWEB) , ... February 15, 2017 , ... ... that Park SmartScan, a powerful AFM operating software that drastically boosts productivity with single ... completely automatizes all of the functions of setting up and taking the image once ...
(Date:2/15/2017)... , Feb. 15, 2017 Windtree ... biotechnology company focused on developing aerosolized KL4 surfactant ... has completed a $10.5 million private placement of ... it has sufficient capital to fund its operations ... trial data release in mid-2017. Windtree ...
Breaking Biology Technology:
(Date:2/13/2017)... -- Former 9/11 Commission border counsel and Special Counsel ... of Identity Strategy Partners, LLP, today releases the ... Order: Protecting the Nation From Foreign Terrorist Entry Into ... President Trump,s ,Travel Ban, Executive Order gains more notoriety ... travel ban, it is important that our national discourse ...
(Date:2/8/2017)... 2017 Report Highlights ... The global synthetic-biology market reached nearly ... 2021, growing at a compound annual growth rate (CAGR) of ... the global markets for synthetic biology. - Analyses of global ... projections of compound annual growth rates (CAGRs) through 2021. - ...
(Date:2/7/2017)... York , February 7, 2017 ... ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or the ... and electronic transaction processing services, is pleased to announce ... the Company. Effective January 31, 2017, ... Board of Directors, CEO and President.  An experienced payment ...
Breaking Biology News(10 mins):